Astragalus and rose composition for preventing and / or treating depression and application thereof

Abstract

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a radix astragali and rose composition for preventing and / or treating depression and application thereof. The radix astragali and rose composition comprises radix astragali 1-6 parts, radix codonopsis 1-2 parts, rose 1-2 parts, gordon euryale seed 1-2 parts, jujube 1-2 parts, pueraria 1-2 parts, mulberry leaf 1-2 parts, and momordica grosvenori 1-2 parts. The results of experiments on a depression pathological model of Caenorhabditis elegans show that the composition has a significant treatment effect on the depression pathological model of Caenorhabditis elegans. Compared with other single-ingredient medicines, the composition has a more significant treatment effect on the depression pathological model of Caenorhabditis elegans. Compared with other single-ingredient medicine compositions disclosed in existing patents, the composition has a more significant treatment effect on the depression pathological model of Caenorhabditis elegans.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to an Astragalus and Rose composition for the prevention and / or treatment of depression and its application. Background Technology

[0002] Depression is a common mental disorder characterized by persistent low mood, loss of interest, and anhedonia, often accompanied by cognitive decline and physical discomfort. Patients with depression frequently exhibit significant oxidative stress imbalance, manifested as excessive accumulation of reactive oxygen species (ROS) and weakened antioxidant defense systems, leading to lipid peroxidation and cellular oxidative damage. Therefore, antidepressant interventions need to achieve multiple effects, including reducing oxidative stress levels, inhibiting ROS production, and increasing levels of neurotransmitters such as serotonin and dopamine. While current first-line antidepressants such as fluoxetine and paroxetine (SSRIs) can alleviate some symptoms, they suffer from delayed onset of action, poor response to first-line treatment in about half of patients, and side effects such as nausea, insomnia, weight gain, and sexual dysfunction with long-term use, severely impacting patient adherence and quality of life. Therefore, finding an effective, safe, and suitable antidepressant strategy for long-term use is an urgent scientific problem to be solved.

[0003] Against this backdrop, Traditional Chinese Medicine (TCM), with its holistic regulatory characteristics involving multiple components, targets, and pathways, has demonstrated unique advantages in the treatment of depression. TCM treatment of depression emphasizes soothing the liver and relieving stagnation, strengthening the spleen and nourishing the heart, and replenishing qi and blood, thereby restoring emotional balance by adjusting the body's overall state. Modern pharmacological research has also confirmed that many TCM compound formulas can exert antidepressant effects by regulating the TLR4 / NLRP3 signaling pathway to inhibit central oxidative stress, regulate neuroinflammation, promote the repair of hippocampal neuronal synaptic plasticity, and increase the levels of neurotransmitters such as 5-HT in the brain. For example, invention patent CN105288054A discloses a TCM formula for treating depression containing Astragalus membranaceus, Codonopsis pilosula, Euryale ferox, and Pueraria lobata, which can inhibit the occurrence of anxiety and depression. Invention patent CN116077563B discloses a TCM composition for treating depression caused by liver and kidney deficiency and its preparation method, which has the effect of treating mild to moderate depression, especially depression caused by liver and kidney deficiency.

[0004] Based on the above research, the inventors obtained an Astragalus and Rose Composition for treating depression during the research process. The Astragalus and Rose Composition includes 1-6 parts of Astragalus membranaceus, 1-2 parts of Codonopsis pilosula, 1-2 parts of Rosa rugosa, 1-2 parts of Euryale ferox, 1-2 parts of Ziziphus jujuba, 1-2 parts of Pueraria lobata, 1-2 parts of Morus alba leaves, and 1-2 parts of Siraitia grosvenorii. This Astragalus and Rose Composition showed significant therapeutic effects in the pathological model of depression caused by Caenorhabditis elegans, and can significantly improve oxidative stress and reduce ROS levels in the body, showing potential for antidepressant applications and can be used to prepare antidepressant drugs. Summary of the Invention

[0005] The primary objective of this invention is to provide an Astragalus and Rose composition for the prevention and / or treatment of depression, wherein the Astragalus and Rose composition comprises 1-6 parts of Astragalus membranaceus, 1-2 parts of Codonopsis pilosula, 1-2 parts of rose petals, 1-2 parts of Euryale ferox, 1-2 parts of jujube, 1-2 parts of Pueraria lobata, 1-2 parts of mulberry leaves, and 1-2 parts of Siraitia grosvenorii.

[0006] Preferably, the Astragalus and Rose Composition comprises the following raw materials in parts by weight: 1-6 parts Astragalus, 1-2 parts Codonopsis, 1-2 parts Rose, 1-2 parts Euryale ferox, 1-2 parts Jujube, 1-2 parts Kudzu root, 1-2 parts Mulberry leaf, and 1-2 parts Siraitia grosvenorii.

[0007] Preferably, the Astragalus and Rose Composition consists of the following raw materials in parts by weight: 3 parts Astragalus, 1 part Codonopsis, 1 part Rose, 1 part Euryale ferox, 1 part Jujube, 1 part Kudzu root, 1 part Mulberry leaf, and 1 part Siraitia grosvenorii.

[0008] Preferably, the Astragalus and Rose Composition consists of the following raw materials in parts by weight: 1 part Astragalus, 1 part Codonopsis, 1 part Rose, 1 part Euryale ferox, 1 part Jujube, 1 part Kudzu root, 1 part Mulberry leaf, and 1 part Siraitia grosvenorii.

[0009] A second objective of this invention is to provide a method for preparing the aforementioned Astragalus and Rose composition, comprising the following steps: S1: Weigh out the following ingredients according to the specified proportions: Astragalus membranaceus, Codonopsis pilosula, rose petals, Euryale ferox, jujube, kudzu root, mulberry leaves, and monk fruit, and set aside. S2: Add water, heat under reflux, and collect the supernatant solution for later use; S3: Take the precipitate of the medicinal residue from step S2, add the same amount of water, heat under reflux, and take the supernatant liquid for later use; S4: Combine the supernatants from S2 and S3 to obtain the final product.

[0010] Preferably, the amount of water added in steps S2 and S3 is 6-15 times the total amount of medicinal materials.

[0011] A third objective of this invention is to provide the use of the aforementioned Astragalus and Rose composition in the preparation of medicaments for the prevention and / or treatment of depression.

[0012] A fourth objective of the present invention is to provide a pharmaceutical composition for treating depression, said pharmaceutical composition comprising the aforementioned Astragalus and Rose composition.

[0013] Preferably, the pharmaceutical composition further includes excipients.

[0014] Preferably, the pharmaceutical composition, together with pharmaceutically acceptable excipients, is prepared into powder, granules, powder, pills, tablets, capsules, pills, or oral liquid.

[0015] The beneficial effects of this invention are: an Astragalus and Rose composition for the prevention and / or treatment of depression, wherein the Astragalus and Rose composition comprises 1-6 parts Astragalus membranaceus, 1-2 parts Codonopsis pilosula, 1-2 parts Rose, 1-2 parts Euryale ferox, 1-2 parts Jujube, 1-2 parts Pueraria lobata, 1-2 parts Morus alba leaves, and 1-2 parts Siraitia grosvenorii; experiments were conducted using a *C. elegans* depression pathological model, and the results showed that the composition has a significant therapeutic effect on the *C. elegans* depression pathological model; compared with other single-herb compositions, the composition has a more significant therapeutic effect on the *C. elegans* depression pathological model. Compared with other single-herb compositions disclosed in existing patents, the composition has a more significant therapeutic effect on the *C. elegans* depression pathological model.

[0016] This invention discloses a traditional Chinese medicine composition of Astragalus and Rose, the raw materials of which are: Astragalus, Codonopsis, Rose, Euryale ferox, Jujube, Kudzu root, Mulberry leaf, and Siraitia grosvenorii. The unique characteristics of the formulation are: Astragalus and Codonopsis ferox are the principal ingredients to invigorate Qi; Euryale ferox and Jujube are the assistant ingredients to strengthen the spleen, nourish blood, and consolidate essence; Rose is used to soothe the liver and relieve stagnation, and Kudzu root to promote the upward movement of Qi and prevent stagnation; Mulberry leaf and Siraitia grosvenorii moisten dryness and clear heat, counteracting the warming and drying effects of Astragalus and Codonopsis ferox, and harmonizing the effects of all the herbs. The main ingredient is Astragalus, a genuine medicinal material and geographical indication product from Dangchang County, Longnan City, Gansu Province, combined with Dangchang Codonopsis ferox and Hetian Jujube to enhance the effects of invigorating Qi and nourishing blood, and harmonizing blood vessels; Rose is used to regulate Qi and blood, and disperse blood stasis and unblock collaterals; Mulberry leaf and Siraitia grosvenorii clear heat and moisten the lungs; Kudzu root relieves muscle tension, reduces fever, and promotes body fluid production and quenches thirst; Euryale ferox strengthens the spleen and dries dampness. The entire formula focuses on invigorating Qi, while also nourishing and regulating blood, and has the unique effects of strengthening the spleen, supporting the body's resistance, and enhancing physical constitution. Attached Figure Description

[0017] Figure 1 The therapeutic effect of Astragalus and Rose Combination on Depressive Nematodes Control group - blank control group; P-positive drug NAC group; 0.01-1-Astragalus and Rose combination group.

[0018] Figure 2 A comparison of the therapeutic effects of Astragalus and Rose combination versus single herbs on depressive nematodes. Control group - Blank control group; P - Positive drug NAC group; A - Astragalus membranaceus group; B - Codonopsis pilosula group; C - Mulberry leaf group; D - Jujube group; E - Euryale ferox group; F - Pueraria lobata group; G - Siraitia grosvenorii group; H - Rose group.

[0019] Figure 3 A comparison of the therapeutic effects of Astragalus and Rose combination versus single-herb combination on depressive nematodes. Control group - blank control group; P group - positive drug NAC group; I group - Astragalus membranaceus + Codonopsis pilosula + Euryale ferox + Jujube group; J group - Astragalus membranaceus + Codonopsis pilosula + Euryale ferox + Pueraria lobata group. Detailed Implementation

[0020] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments. Of course, the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0021] It should be noted that the formulations of the traditional Chinese medicine compositions in the embodiments can be appropriately selected based on commonly used excipients in the pharmaceutical field, according to the dosage form and actual conditions. For example, common excipients include starch, low-substituted hydroxypropyl cellulose, micronized silica gel, magnesium stearate, starch paste, sucrose, dextrin, sodium carboxymethyl starch, talc, polysorbate, polyethylene glycol, etc. When preparing various dosage forms of the desired drug, they can be prepared according to conventional production methods in the pharmaceutical field, such as mixing the compound with one or more carriers and then preparing the corresponding dosage form. Preferably, the dosage forms of the drug preparations include tablets, pills, granules, capsules, and compound preparations.

[0022] It should be noted that the following embodiments only provide the dosage for application to nematodes. When applied to other organisms, the dosage needs to be changed proportionally.

[0023] It should be noted that, unless otherwise specified, the methods described in the following embodiments are all conventional methods, and the reagents / consumables can all be purchased from the market.

[0024] Example 1: Preparation method of Astragalus and Rose Composition Astragalus and Rose Combination 1: Weigh 3g of Astragalus membranaceus from Dangchang, 1g of Codonopsis pilosula, 1g of rose petals, 1g of Euryale ferox, 1g of jujube, 1g of Pueraria lobata, 1g of mulberry leaf, and 1g of Siraitia grosvenorii. Add 200mL of water and heat under reflux for 1 hour. Collect the supernatant. Collect the precipitate, add the same amount of water, and heat under reflux again for 1 hour. Collect the supernatant and set aside. Repeat twice, combine the supernatants, and store for later use.

[0025] Astragalus and Rose Combination 2: Weigh 1g of Astragalus membranaceus, 1g of Codonopsis pilosula, 1g of rose petals, 1g of Euryale ferox, 1g of jujube, 1g of Pueraria lobata, 1g of mulberry leaf, and 1g of Siraitia grosvenorii. Add 200mL of water and heat under reflux for 1 hour. Collect the supernatant. Collect the precipitate, add the same amount of water, and heat under reflux again for 1 hour. Collect the supernatant and set aside. Repeat twice, combine the supernatants, and store for later use.

[0026] Astragalus and Rose Combination 3: Weigh 6g of Astragalus membranaceus from Dangchang, 2g of Codonopsis pilosula, 1g of rose petals, 1g of Euryale ferox, 2g of jujube, 1g of Pueraria lobata, 1g of mulberry leaf, and 1g of Siraitia grosvenorii. Add 200mL of water and heat under reflux for 1 hour. Collect the supernatant. Collect the precipitate, add the same amount of water, and heat under reflux again for 1 hour. Collect the supernatant and set aside. Repeat twice, combine the supernatants, and store for later use.

[0027] The inventors conducted preliminary experiments to evaluate the therapeutic effect of the above-mentioned composition on a depression model. The results showed that the Astragalus and Rose Composition 1 had a significant therapeutic effect on depression, which was significantly better than that of Astragalus and Rose Composition 2 and Astragalus and Rose Composition 3. Therefore, in the subsequent embodiments, Astragalus and Rose Composition 1 was used as the standard.

[0028] Example 2: Therapeutic effect of traditional Chinese medicine composition on a depression model 1. Biomaterials: (1) The mutant strain of Caenorhabditis elegans, AQ866, was purchased from CGC; (2) Escherichia coli OP50 (uracil-deficient mutant), purchased from CGC, was used as food for Caenorhabditis elegans.

[0029] 2. Reagents (1) Composition and preparation of solid NGM culture medium (taking 1L as an example) Solid NGM medium composition: NaCl 3.00 g, K2HPO4 2.34 g, KH2PO4 17.23 g, peptone 2.50 g, agar 17.00 g, H2O added to 1000.

[0030] After preparing the solid NGM medium, autoclave it at 121°C for 20 min. Under aseptic conditions, add 1 mL of 5 mg / mL cholesterol, 1 mL of 1 M MgSO4, and 1 mL of 1 M CaCl2, and mix well. While still hot, pour the mixture into sterilized 9 cm culture plates, approximately 20 mL per plate. Let it stand until the medium solidifies, then set aside for later use.

[0031] (2) M9 buffer formulation: Na2HPO4 6.00 g, KH2PO4 3.00 g, NaCl 5.00 g, 1M MgSO4 1.00 mL, add H2O to 1000 mL.

[0032] (3) Preparation of lysis buffer: 6.4% NaClO solution and 1M NaOH solution are mixed at a volume ratio of 1:1.

[0033] 3. Preparation of NGM plates containing Astragalus and Rose Composition Preparation of the Astragalus and Rose Composition: Prepare the supernatant of the pre-prepared Astragalus and Rose Composition. Prepare NGM plates containing the Astragalus and Rose Composition: Add the Astragalus and Rose Composition at an appropriate dilution to NGM medium and invert the plates. The final concentration of the Astragalus and Rose Composition is the same as the initial stock solution, diluted 10-fold and then 100-fold. Allow the medium to solidify. Evenly spread E. coli OP50 onto the medium as food for the nematodes.

[0034] 4. Implementation Steps (1) Cultivation of nematodes: Nematodes were inoculated onto solid NGM plates coated with Escherichia coli OP50 and then cultured in an incubator at 20°C. When the nematodes grew to adulthood, they were synchronized.

[0035] (2) Nematode synchronization: Select NGM medium containing a large number of adult nematodes and some hatched nematode eggs. Use M9 solution to flush the nematodes off the medium and transfer them to centrifuge tubes. Let them stand to allow the nematodes to settle freely to the bottom of the tubes and discard the supernatant. Add lysis buffer to the centrifuge tubes according to the amount of nematodes. Vortex for 5-7 minutes until all the nematodes break down. Stop vortexing and aliquot into 1.5 mL centrifuge tubes. Wash the nematode eggs three times with M9 solution.

[0036] (3) Experimental group grouping Blank control group (Control); Positive drug NAC group (P); 0.01-1 dilution of Astragalus and Rose Combination Group.

[0037] Positive drug NAC group: The purchased stock solution was 10mM and diluted 2000 times during the experiment, with a final concentration of 5μM.

[0038] The preparation of the Astragalus and Rose composition was as shown in Example 1. The resulting liquid was used as the working solution and diluted 0, 5, 10, and 100 times when preparing NGM medium to obtain groups of diluted Astragalus and Rose compositions: group 1, group 0.2, group 0.1, and group 0.01.

[0039] (4) The therapeutic effect of Astragalus and Rose Combination on Oxidative Stress in Transgenic Caenorhabditis elegans Model To synchronize nematodes, L1-stage nematodes were inoculated onto NGM medium containing different concentrations of the drug, with 400-600 nematodes inoculated onto each plate. They were incubated at 20°C until the L3 stage. The nematodes were then washed off the medium with M9 buffer and collected into centrifuge tubes. After washing three times with M9 buffer to remove excess bacteria, the supernatant was discarded after centrifugation. 100 μL of 1 mM H2DCF-DA solution was added and the tubes were treated for 2 hours at the designated incubation temperature for each strain. After treatment, the H2DCF-DA solution was discarded after centrifugation, and the nematodes were washed three times with M9 buffer. The washed nematodes were then transferred to fresh NGM medium containing the corresponding drug and allowed to crawl freely for 30 minutes to encourage the nematodes to expel excess H2DCF-DA solution from their intestines, thus reducing background fluorescence. Finally, the nematodes were washed off the medium with M9 buffer to ensure thorough cleaning. 20 μL of nematodes were placed on a glass slide and fixed with 20 μL of NaN3 (20 mM). ROS staining of the nematodes was recorded under the GFP fluorescence channel of an upright fluorescence microscope. Nematodes were randomly observed and photographed. Data were processed using ImageJ software to calculate the average fluorescence intensity throughout the nematodes. Three replicate groups were set up for each experiment, with at least 15 nematodes in each group.

[0040] (5) Experimental results The Astragalus and Rose combination showed significant therapeutic effects on the pathological model of depression caused by Caenorhabditis elegans. Figure 1 The average fluorescence intensity of nematodes in the dilution groups of 0.2, 0.1, and 0.01 decreased by 14.42%, 5.43%, and 2.74% respectively compared with the blank control group. The average fluorescence intensity of nematodes in the dilution group of 0.2 decreased by 4.42% compared with the positive control group.

[0041] Example 3: Comparison of the therapeutic effects of Astragalus and Rose Combination and Single Herbs on Depressive Nematodes 1. Experimental group setup Blank control group (Control); Positive drug NAC group (P); Astragalus and rose combination group (M); Dangchang Astragalus group (A); Codonopsis group (B); Mulberry leaf group (C); Jujube group (D); Euryale seed group (E); Kudzu root group (F); Luo Han Guo group (G); Rose group (H).

[0042] Astragalus and Rose Composition (M): Prepared as shown in Example 1.

[0043] Drug Group A: 18g of Astragalus membranaceus from Dangchang was added to 100ml of water and heated under reflux for 1 hour. The supernatant was collected, and the residue was added to a certain amount of water and heated under reflux for 1 hour. This process was repeated twice. The supernatants from the three batches were combined and set aside for later use.

[0044] Group B: 6g of Codonopsis pilosula was added to 100ml of water and heated under reflux for 1 hour. The supernatant was collected, and the residue was added to a certain amount of water and heated under reflux for 1 hour. This process was repeated twice. The supernatants from the three batches were combined and set aside for later use.

[0045] Drug group C: 6g of mulberry leaves, added to 100ml of water, heated under reflux for 1 hour, and the supernatant was collected. The residue was added to a certain amount of water and heated under reflux for 1 hour. The above operation was repeated twice. The supernatants from the three batches were combined and set aside.

[0046] Group D: 6g of jujubes were added to 100ml of water and heated under reflux for 1 hour. The supernatant was collected, and the residue was added to a certain amount of water and heated under reflux for 1 hour. This process was repeated twice. The supernatants from the three batches were combined and set aside for later use.

[0047] Group E: 6g of Euryale ferox seeds, added to 100ml of water, heated under reflux for 1 hour, and the supernatant was collected. The residue was added to a certain amount of water and heated under reflux for 1 hour. This process was repeated twice. The supernatants from the three batches were combined and set aside.

[0048] Drug group F: 6g of kudzu root, added to 100ml of water, heated under reflux for 1 hour, and the supernatant was collected. The residue was added to a certain amount of water and heated under reflux for 1 hour. The above operation was repeated twice. The supernatants from the three batches were combined and set aside.

[0049] Group G: 6g of monk fruit, added to 100ml of water, heated under reflux for 1 hour, and the supernatant was collected. The residue was added to a certain amount of water and heated under reflux for 1 hour. This process was repeated twice. The supernatants from the three batches were combined and set aside.

[0050] Drug group H: 6g of rose petals, added to 100ml of water, heated under reflux for 1 hour, and the supernatant was collected. The residue was added to a certain amount of water and heated under reflux for 1 hour. The above operation was repeated twice. The supernatants from the three batches were combined and set aside.

[0051] 2. The implementation steps are the same as in Example 2.

[0052] 3. Experimental Results Experimental results are as follows Figure 2 The results showed that the Astragalus and Rose combination (M) had a significant therapeutic effect on the Caenorhabditis elegans depression pathological model, and the effect was superior to that of any single herb. Compared with the blank control group, the average fluorescence intensity of nematodes in the M group, A group, B group, C group, D group, E group, F group, G group, and H group decreased by 14.42%, 6.59%, 7.89%, 9.10%, 10.66%, 2.34%, 10.56%, 9.79%, and 8.44%, respectively. Compared with the positive control group, the average fluorescence intensity of nematodes in the M group, D group, and F group decreased by 4.42%, 0.21%, and 0.10%, respectively.

[0053] Example 4: Comparison of the therapeutic effects of Astragalus and Rose Combination and Single-Herb Combinations on Depressive Nematodes 1. Experimental group setup The efficacy of this Astragalus and Rose herbal composition was compared with that of compositions containing the same herbal ingredients found in existing literature.

[0054] Blank control group (Control); positive control group (NAC) (P); Astragalus and rose combination group (M); Astragalus membranaceus + Codonopsis pilosula + Euryale ferox + Jujube group (I); Astragalus membranaceus + Codonopsis pilosula + Euryale ferox + Pueraria lobata group (J).

[0055] Among them, Astragalus and Rose Composition 1 (M): prepared as shown in Example 1.

[0056] Group I: 18g of Astragalus membranaceus, 6g of Codonopsis pilosula, 6g of Euryale ferox, and 6g of Ziziphus jujuba. Add a certain amount of water and heat under reflux for 1 hour. Collect the supernatant. Collect the precipitate, add the same amount of water, and heat under reflux again for 1 hour. Collect the supernatant for later use. Repeat twice. Combine the supernatants and store for later use.

[0057] Drug group J: 18g of Astragalus membranaceus from Dangchang, 6g of Codonopsis pilosula, 6g of Euryale ferox, and 6g of Pueraria lobata. Add a certain amount of water and heat under reflux for 1 hour. Collect the supernatant. Collect the precipitate, add the same amount of water, and heat under reflux again for 1 hour. Collect the supernatant for later use. Repeat twice. Combine the supernatants and store for later use.

[0058] 2. The implementation steps are the same as in Example 2. 3. Experimental Results Experimental results are as follows Figure 3 The results showed that the Astragalus and Rose combination group (M), drug group I, and drug group J all had significant therapeutic effects on the Caenorhabditis elegans depression pathological model, with the Astragalus and Rose combination group (M) showing better efficacy than drug groups I and J. Compared with the blank control group, the average fluorescence intensity of nematodes in drug groups M, I, and J decreased by 14.42%, 9.45%, and 11.25%, respectively. Compared with the positive control group, the average fluorescence intensity of nematodes in drug groups M and J decreased by 4.42% and 0.87%, respectively.

[0059] The results of the above embodiments demonstrate that the Astragalus and Rose composition can significantly alleviate oxidative stress in nematodes and reduce ROS levels within them. The Astragalus and Rose composition also exhibits a significant therapeutic effect on a Caenorhabditis elegans depression model. This suggests that the Astragalus and Rose composition has the potential to treat depression and can be used in the preparation of drugs for treating depression, as well as in the preparation of health products for the prevention and adjunctive treatment of depression. It holds promise for the development of next-generation antidepressants or preventative health products or beverages for depression.

[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An Astragalus and Rose Composition for the Prevention and / or Treatment of Depression, characterized in that, The aforementioned Astragalus and Rose composition comprises 1-6 parts Astragalus membranaceus, 1-2 parts Codonopsis pilosula, 1-2 parts Rose, 1-2 parts Euryale ferox, 1-2 parts Jujube, 1-2 parts Kudzu root, 1-2 parts Mulberry leaf, and 1-2 parts Siraitia grosvenorii.

2. The Astragalus and Rose Composition as described in claim 1, characterized in that, The Astragalus and Rose Composition comprises the following raw materials in parts by weight: 1-6 parts Astragalus membranaceus, 1-2 parts Codonopsis pilosula, 1-2 parts Rose, 1-2 parts Euryale ferox, 1-2 parts Jujube, 1-2 parts Pueraria lobata, 1-2 parts Mulberry leaf, and 1-2 parts Siraitia grosvenorii.

3. The Astragalus and Rose Composition as described in claim 2, characterized in that, The Astragalus and Rose Composition consists of the following raw materials in parts by weight: 3 parts Astragalus, 1 part Codonopsis, 1 part Rose, 1 part Euryale ferox, 1 part Jujube, 1 part Kudzu root, 1 part Mulberry leaf, and 1 part Siraitia grosvenorii.

4. The Astragalus and Rose Composition as described in claim 2, characterized in that, The Astragalus and Rose Composition consists of the following raw materials in parts by weight: 1 part Astragalus, 1 part Codonopsis, 1 part Rose, 1 part Euryale ferox, 1 part Jujube, 1 part Kudzu root, 1 part Mulberry leaf, and 1 part Siraitia grosvenorii.

5. The method for preparing the Astragalus and Rose composition according to any one of claims 1-4, characterized in that, Includes the following steps: S1: Weigh out the following ingredients according to the specified proportions: Astragalus membranaceus, Codonopsis pilosula, rose petals, Euryale ferox, jujube, kudzu root, mulberry leaves, and monk fruit, and set aside. S2: Add water, heat under reflux, and collect the supernatant solution for later use; S3: Take the precipitate of the medicinal residue from step S2, add the same amount of water, heat under reflux, and take the supernatant liquid for later use; S4: Combine the supernatants from S2 and S3 to obtain the final product.

6. The preparation method according to claim 5, characterized in that, The amount of water added in steps S2 and S3 is 6-15 times the total amount of medicinal materials.

7. The use of the Astragalus and Rose composition according to any one of claims 1-4 in the preparation of a medicament for the prevention and / or treatment of depression.

8. A pharmaceutical composition for treating depression, characterized in that, The pharmaceutical composition comprises the Astragalus and Rose composition according to any one of claims 1-4.

9. The pharmaceutical composition according to claim 8, characterized in that, The pharmaceutical composition also includes excipients.

10. The pharmaceutical composition according to claim 8, characterized in that, The pharmaceutical composition, together with pharmaceutically acceptable excipients, is prepared into powder, granules, powder, pills, tablets, capsules, pills, or oral liquid.

Images